What is stem cell treatment for multiple sclerosis (MS)?
Stem cell treatment for multiple sclerosis (MS) most commonly refers to haematopoietic stem cell transplantation (HSCT), a procedure that uses the patient's own blood stem cells to reset the immune system. In MS, the immune system mistakenly attacks the myelin sheath around nerve fibres; HSCT aims to stop that attack by destroying the faulty immune cells and rebuilding immunity from stem cells collected before treatment. The approach is not a simple infusion of cells — it is a carefully staged medical programme that takes place in a licensed haematology unit over several weeks. For the broader context of cell-based therapies, see our guide to regenerative treatments in Turkey.
A smaller number of clinics also offer mesenchymal stem cell (MSC) infusions, which aim to reduce inflammation rather than reset immunity. The evidence base for MSC therapy in MS is early-stage and it is not the same procedure as HSCT; this guide covers both and explains the difference.
How does HSCT for MS work, step by step?
HSCT follows four main stages. First, the patient receives a growth-factor injection (usually G-CSF) over several days to push stem cells out of the bone marrow and into the bloodstream, where they are collected by a process called apheresis — the blood passes through a machine that separates and stores the stem cells. Second, a conditioning regimen of chemotherapy drugs (and sometimes low-dose radiotherapy, depending on the protocol) is given over four to seven days to suppress or largely eliminate the existing immune system. Third, the stored stem cells are returned to the patient through a drip, where they migrate to the bone marrow and begin rebuilding a new immune system over the following weeks. Fourth, the patient is monitored closely in a protective environment while the new immune system establishes itself — a period when the risk of infection is highest.
The intensity of the conditioning regimen — described as myeloablative (full) or non-myeloablative (reduced intensity) — varies between protocols. The MIST trial, one of the largest randomised studies to date, used a non-myeloablative regimen and showed significantly better outcomes than continued disease-modifying therapy in relapsing MS. The choice of protocol affects both efficacy and risk, and should be discussed in detail with the treating team.
Does stem cell treatment for MS actually work? What does the evidence say?
For relapsing-remitting MS (RRMS), the evidence is the strongest it has been. The MIST trial (published in JAMA, 2019) showed that HSCT produced significantly fewer relapses and better disability outcomes than best available disease-modifying therapy over five years in patients with active relapsing MS. Long-term follow-up data from multiple centres — including the EBMT registry — report that a substantial proportion of patients have no detectable disease activity for many years after HSCT. Some patients show partial neurological improvement; most experience stabilisation rather than reversal of established disability.
For secondary progressive MS or primary progressive MS, the evidence is weaker. HSCT is not widely recommended for these forms because the damage in progressive disease is driven more by neurodegeneration than by active inflammation, and removing the inflammatory attack has less impact once the degenerative process dominates.
MSC infusions have been studied in phase I and II trials showing acceptable safety and some signals of reduced inflammation, but no phase III trial has yet confirmed clinical benefit in MS. Clinics offering MSC therapy should be clear about the experimental status of the treatment. The treatment with stem cells page has more detail on how clinics in Turkey approach cell therapy programmes.
No form of stem cell therapy currently approved anywhere offers a cure for MS, and any clinic that uses that word should be treated with caution.
Stem cell treatment for MS cost in Turkey compared with the UK, US and Germany
The figures below are approximate ranges for the full HSCT programme. They depend on the conditioning protocol chosen, the length of the hospital stay, monitoring costs and what is included in the package. Each hospital confirms its own price in a written quote; the figures below are not hospital-specific.
| Country | Approximate cost range (HSCT programme) |
|---|---|
| Turkey | €20,000 – €45,000 |
| United Kingdom | €50,000 – €90,000 (private); NHS access is restricted |
| United States | €80,000 – €150,000 |
| Germany | €50,000 – €100,000 |
What changes the price: the conditioning protocol (non-myeloablative costs less than myeloablative), the duration of inpatient stay (typically three to six weeks for HSCT), the extent of pre-treatment assessment, the number of post-discharge follow-up visits and whether supportive medications such as anti-fungal and anti-viral prophylaxis are included. A package should list in writing what is covered — apheresis, conditioning, the transplant, inpatient nursing, isolation facilities, medications and at least one outpatient review. Request this breakdown before paying any deposit. To start the process, use our free quote page.
Who is a good candidate for HSCT, and who is not?
HSCT is generally considered for adults with relapsing-remitting MS who have continued to relapse despite adequate trials of high-efficacy disease-modifying therapy. Most protocols require active inflammatory disease confirmed on MRI (new or enhancing lesions), an EDSS disability score broadly between 2.0 and 6.0, and adequate organ function to tolerate chemotherapy. Age limits vary by protocol but many centres prefer patients under 50 for full myeloablative regimens.
People who are less suited include those with primary or secondary progressive MS without active inflammation on MRI, individuals with significant heart, lung, liver or kidney disease that raises the risk of chemotherapy, those with active serious infection, and patients with severe or advanced disability where the risk-benefit balance is unfavourable. The assessment process — including a full neurological review, MRI, blood tests and organ function tests — is therefore essential before any decision is made.
HSCT versus high-efficacy disease-modifying therapies: how do they compare?
HSCT is not a first-line treatment; it is considered when other options have been tried or are unsuitable. The table below compares it with the two nearest treatment categories a person with active relapsing MS is likely to consider.
| Approach | Best suited to | Key limits |
|---|---|---|
| HSCT | Active RRMS failing disease-modifying therapy; aim to stop inflammation long-term with a single procedure | Significant short-term risk; requires specialist haematology unit; not effective in pure progressive disease |
| High-efficacy DMTs (e.g. alemtuzumab, cladribine, ocrelizumab) | Active RRMS; ongoing annual or periodic dosing | Requires continued treatment or monitoring; each drug carries its own risk profile |
| MSC infusions | Patients seeking a lower-risk investigational option or who do not qualify for HSCT | Evidence still early-stage; benefit not yet confirmed in phase III trials |
A neurologist with experience in both HSCT and DMTs should advise on the choice. Our process can help connect you with centres that offer a thorough pre-assessment before any commitment.
What does the stem cell treatment programme feel like, and how long does it take?
The full HSCT programme typically requires three to six weeks in Turkey. The mobilisation injections are given over four to five days, often as an outpatient. Apheresis (stem cell collection) takes one to two days. Conditioning chemotherapy is given over four to seven days in hospital. The transplant itself is a straightforward intravenous infusion lasting a few hours. The most demanding phase follows — the engraftment period of two to four weeks — during which the immune system is at its lowest and the patient stays in a protected (sometimes isolated) hospital environment. During this time fatigue, nausea, mouth soreness and susceptibility to infection are common. Once blood counts recover to safe levels, discharge and a period of outpatient monitoring follow before the patient is considered fit to travel home.
Patients often describe the conditioning phase as the most physically challenging part. The months after transplant involve gradual recovery: energy levels improve slowly, and most people are advised to avoid crowded places and limit strenuous activity for several months while the new immune system strengthens.
Stem cell treatment for MS: before and after — realistic expectations
Published data and patient registries give a clearer picture than individual clinic case studies. In the MIST trial, 78% of HSCT patients showed no evidence of disease activity at three years versus 60% on DMTs. Many patients report no new relapses after the procedure; some describe partial recovery of function in areas affected by recent inflammation, particularly in the months following engraftment. Established disability caused by long-standing nerve damage is less likely to reverse.
Realistic before-and-after expectations therefore include: a high probability of relapse suppression in suitable candidates, possible partial functional improvement in recently affected areas, and stabilisation rather than cure of existing disability. Recovery of fatigue and cognitive fog is variable. Ask any clinic to share published outcomes data or registry results rather than selected individual stories.
Recovery milestones after HSCT for MS
The pace of recovery varies, but broad milestones are:
- Weeks 1–4 (in hospital): Conditioning chemotherapy, transplant and engraftment. The immune system is at its lowest; infection prevention is the priority.
- Weeks 4–8: Blood counts recover; most patients are discharged to outpatient care. Fatigue is prominent. Light walking is encouraged; crowded places and sick contacts should be avoided.
- Months 2–6: Gradual return of energy. Routine tasks are usually manageable. Prophylactic antiviral and antifungal medications continue. Neurological symptoms may fluctuate before settling.
- Months 6–12: Immune reconstitution continues. Most patients have returned to everyday activities, though high-intensity exercise and return to work depend on individual progress. MRI is usually repeated at six or twelve months.
- Year 2 onwards: Long-term monitoring with periodic MRI and blood tests. Some vaccinations need to be repeated once the immune system has rebuilt.
Risks of stem cell treatment for multiple sclerosis
HSCT carries meaningful risks that must be weighed carefully against the risks of continued MS activity. The most serious early risk is infection during the period when the immune system is ablated. Procedure-related mortality in published series from experienced centres ranges from less than 0.3% (non-myeloablative) to around 1% (myeloablative), according to data reported in the EBMT registry and JAMA. Other risks include febrile neutropenia, mucositis, secondary autoimmune conditions (particularly thyroid disorders), infertility (dependent on conditioning regimen and age), and very rarely secondary malignancy. Fatigue, hair loss and nausea during conditioning are almost universal but temporary. The NHS and professional haematology societies advise that HSCT for MS should only be performed in centres with specific experience in the procedure, not general oncology units. Ask what complications the centre has treated and what their protocol is if a problem arises after you return home.
How to choose a clinic for stem cell treatment for MS, and red flags
Key questions when evaluating a centre: Is the unit accredited for haematological stem cell transplantation (JACIE or equivalent)? Is there a neurologist with MS expertise involved in the pre-assessment, not just a haematologist? Does the centre publish or share outcome data? Is there a named protocol (e.g. BEAM, Cy/ATG) with a clear explanation of why it suits your disease profile? What infection prevention protocols are in place during engraftment?
Red flags include centres that offer HSCT without a neurology pre-assessment, clinics that describe the treatment as a cure or guarantee improvement, centres with no published or verifiable outcomes, quotes with no breakdown of what is included, and pressure to decide quickly without time for a second neurological opinion. Our how it works page explains how we support patients through the assessment process, and you can begin with a free quote that includes a written treatment plan.
Questions to ask the clinic before committing:
- What conditioning protocol do you use and why is it appropriate for my EDSS and disease activity?
- How many HSCT procedures for MS has your centre performed, and what are your published or audited outcomes?
- Is the unit JACIE-accredited or equivalent?
- Which neurologist will review my MRI and clinical history before the procedure?
- What infection prevention measures are in place during engraftment?
- What happens if I develop a complication after returning home?
- What vaccinations will I need to repeat, and when?
Conditions treated with Stem Cell Treatment for Multiple Sclerosis (MS)
Hospitals with Regenerative Medicine in Turkey
Frequently asked questions
The most studied form is haematopoietic stem cell transplantation (HSCT), which uses the patient's own blood stem cells to rebuild the immune system after chemotherapy destroys the cells attacking the myelin sheath. Mesenchymal stem cell (MSC) infusions are a separate, earlier-stage approach aimed at reducing inflammation.
For relapsing-remitting MS with active disease, the evidence is strong: the MIST trial showed HSCT significantly outperformed best available disease-modifying therapy over five years. Most suitable patients experience relapse suppression; some see partial neurological improvement. For progressive MS, the evidence is much weaker.
Approximate ranges for a full HSCT programme are €20,000 to €45,000 in Turkey, compared with €50,000 to €90,000 privately in the UK. The price depends on the conditioning protocol, length of stay and what the package includes; each centre gives a written quote.
The full inpatient programme typically takes three to six weeks — covering mobilisation, collection, conditioning chemotherapy, the transplant and the engraftment monitoring period. A further period of outpatient monitoring usually follows before the team clears you to fly home.
Adults with relapsing-remitting MS who have continued to relapse despite high-efficacy disease-modifying therapy and who have active inflammation on MRI are generally considered. Progressive MS without active inflammation, significant organ disease or advanced disability are typical reasons not to proceed.
Published registry data show that the majority of suitable patients have no new relapses for several years after HSCT. Some partial recovery of recent neurological deficits is possible; long-standing disability from previous damage is unlikely to reverse. Stabilisation is the most common and evidence-backed outcome.
The conditioning chemotherapy phase — typically four to seven days — is the hardest part, commonly causing nausea, fatigue and mouth soreness. The stem cell collection and the actual transplant infusion are not particularly painful. The engraftment period in hospital requires staying in a protected environment for two to four weeks.
In experienced, accredited centres, procedure-related mortality for non-myeloablative HSCT is reported at below 0.3% in published series. Serious risks include infection during the low-immune period, secondary autoimmune conditions and, depending on the regimen, effects on fertility. The risk profile must be weighed against the risks of ongoing active MS.
Both aim to reset or suppress the abnormal immune response. HSCT is a single procedure with significant short-term risk but potentially durable long-term suppression. High-efficacy DMTs require ongoing or repeated dosing and each carries its own risk profile. A neurologist experienced in both options should advise.
HSCT rebuilds the immune system using the patient's blood-forming stem cells after chemotherapy; it has the strongest evidence base for relapsing MS. MSC infusions use a different cell type to reduce inflammation and support repair, but are still investigational — phase III trials confirming clinical benefit in MS have not yet been completed.